The hypothesis that SGLT2 inhibitors may have pleiotropic effects appears to be supported by other observations from the clinical trial data, not least that SGLT2 inhibition appears to have minimal impact upon the cardiovascular event rate—be it myocardial infarction or stroke, admissions with unstable angina or the need for a coronary revascularization procedure 1, 2. Here, SLC5A2 is linked to stroke disorder.